Invitae, a maker of a wide array of low-cost genetic medical tests, has reached a deal to acquire Singular Bio to expand its ability to screen babies for disease during the early months of pregnancy.

Invitae (NYSE: NVTA) said Monday it will pay $55 million in cash and stock to acquire privately held Singular Bio. Both companies are based in San Francisco. In addition, Invitae will pay up to $90 million in stock to Singular Bio employees who stay with Invitae after the acquisition. Those stock awards are tied to milestones for the Singular technology.

Singular Bio’s technology, which is… Read more »